Ann S. LaCasce, MD, shares data from the Alliance for Clinical Trials in Oncology's CALGB-50801 trial, which evaluated a PET-adapted approach to cHL therapy.
Skip Nav Destination
Ann LaCasce: PET Adapted Therapy Allows Omission of Radiation Therapy in Classic Hodgkin Lymphoma
December 30, 2021
Content License:Private